Published :
Tables : 58
Figures : 47
Category : Healthcare
No. of Pages : 223
Report Code : HC-U3253
Hydroxychloroquine Market valued over 540 million with a CAGR of over 30% in 2019 and it is expected to exhibit a significant growth rate owing to the current COVID-19 outbreak. Hydroxychloroquine Market Introduction: COVID-19 is the disease that is caused by the newly found coronavirus, has affected over 200 countries. This disease is mainly transmitted by saliva and mucus droplets of an infected patient. There are no specific vaccines or treatments available for the COVID-19. Currently, many research activities and clinical trials are being conducted for developing vaccines. The hydroxychloroquine, which is an anti-malarial drug. This drug is also utilised for treating Q fever, lupus erythematosus, rheumatoid arthritis and it is being discussed that it can be used for treating COVID-19. The hydroxychloroquine, when combined with a common antibiotic azithromycin, can be effective in treating COVID-19. Through lab testing and in-vivo studies, it has been estimated that hydroxychloroquine shall prove to be a game changer in terms of COVID-19 treatment. India is one of the leading producers of hydroxychloroquine and with the rising global hydroxychloroquine market demand, multiple Indian pharmaceutical companies have escalated the production of this drug. As of now, India produces over 20 crore 200 mg tablets per month. This drug is not developed in the United States and Europe as these regions don’t face a malarial outbreak which has increased the demand of hydroxychloroquine in countries like Italy, Spain, U.S.A; countries with the highest number of COVID-19 patients. The global market is fragmented into dosage type, application, distribution channel and region. The dosage type segment is further classified into 100mg, 200mg and 400mg. The 400mg tablets are on a high demand as they can effectively be used for treating COVID-19 with once a week dosage. The application segment is further categorised into malaria, rheumatoid arthritis, COVID-19, Q fever, PCT and others. The COVID-19 segment shall escalate its growth throughout the forecast period with the emergence of this pandemic since December 2019 in Wuhan, China. Private and public hospitals across the world have started treating their COVID-19 patients with hydroxychloroquine. The distribution channel segment is bifurcated into hospital pharmacy, retail pharmacy, online pharmacy and specialty drug stores. The hospital pharmacy segment is predicted to hold the largest hydroxychloroquine market share over the forecast period. With the recent outbreak, administrations across the world have restrained the public sale of hydroxychloroquine, particularly without a prescription. Key market players associated are Novartis International AG, Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Prasco Laboratories, Cardinal Health, Concordia Pharmaceuticals Inc., Intas Pharmaceuticals, Cipla, McW Healthcare of Indore, Macleods Pharmaceuticals, Bengal Chemicals & Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Covis Pharmaceuticals, Inc., Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Lupin Pharmaceutical, Sun Pharmaceutical Industries Ltd. Ipca Laboratories, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Wallace Pharmaceuticals. Sanofi has revamped the production of hydroxychloroquine with over 90% capacity during the outbreak. Similarly, Amneal Pharmaceuticals Inc. donated over 3.2 million tablets of hydroxychloroquine sulphate in Louisiana and New York. Furthermore, Laurus Labs Ltd. produced over two lakh hydroxychloroquine tablets to the government of Telangana, India. The West Bengal Drug Controller approved the licensing of Bengal Chemicals & Pharmaceuticals Ltd. for producing hydroxychloroquine tablets. They have manufactured over 780,000 tablets and they have a demand of over 2 million tablets from over 16 Indian states. Hydroxychloroquine Market Segmentation: By Dosage Type 100mg 200mg 400mg By Application Malaria COVID-19 Rheumatoid Arthritis Q Fever PCT Others By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Drug Stores By Region North America Europe Asia Pacific Latin America Middle East and Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global hydroxychloroquine market by dosage type, by application, by distribution channel and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered is free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Hydroxychloroquine Market Introduction:
COVID-19 is the disease that is caused by the newly found coronavirus, has affected over 200 countries. This disease is mainly transmitted by saliva and mucus droplets of an infected patient. There are no specific vaccines or treatments available for the COVID-19. Currently, many research activities and clinical trials are being conducted for developing vaccines. The hydroxychloroquine, which is an anti-malarial drug. This drug is also utilised for treating Q fever, lupus erythematosus, rheumatoid arthritis and it is being discussed that it can be used for treating COVID-19. The hydroxychloroquine, when combined with a common antibiotic azithromycin, can be effective in treating COVID-19.
Through lab testing and in-vivo studies, it has been estimated that hydroxychloroquine shall prove to be a game changer in terms of COVID-19 treatment. India is one of the leading producers of hydroxychloroquine and with the rising global hydroxychloroquine market demand, multiple Indian pharmaceutical companies have escalated the production of this drug. As of now, India produces over 20 crore 200 mg tablets per month. This drug is not developed in the United States and Europe as these regions don’t face a malarial outbreak which has increased the demand of hydroxychloroquine in countries like Italy, Spain, U.S.A; countries with the highest number of COVID-19 patients.
The global market is fragmented into dosage type, application, distribution channel and region. The dosage type segment is further classified into 100mg, 200mg and 400mg. The 400mg tablets are on a high demand as they can effectively be used for treating COVID-19 with once a week dosage. The application segment is further categorised into malaria, rheumatoid arthritis, COVID-19, Q fever, PCT and others. The COVID-19 segment shall escalate its growth throughout the forecast period with the emergence of this pandemic since December 2019 in Wuhan, China. Private and public hospitals across the world have started treating their COVID-19 patients with hydroxychloroquine. The distribution channel segment is bifurcated into hospital pharmacy, retail pharmacy, online pharmacy and specialty drug stores. The hospital pharmacy segment is predicted to hold the largest hydroxychloroquine market share over the forecast period. With the recent outbreak, administrations across the world have restrained the public sale of hydroxychloroquine, particularly without a prescription.
Key market players associated are Novartis International AG, Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Prasco Laboratories, Cardinal Health, Concordia Pharmaceuticals Inc., Intas Pharmaceuticals, Cipla, McW Healthcare of Indore, Macleods Pharmaceuticals, Bengal Chemicals & Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Covis Pharmaceuticals, Inc., Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Lupin Pharmaceutical, Sun Pharmaceutical Industries Ltd. Ipca Laboratories, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Wallace Pharmaceuticals.
Sanofi has revamped the production of hydroxychloroquine with over 90% capacity during the outbreak. Similarly, Amneal Pharmaceuticals Inc. donated over 3.2 million tablets of hydroxychloroquine sulphate in Louisiana and New York. Furthermore, Laurus Labs Ltd. produced over two lakh hydroxychloroquine tablets to the government of Telangana, India. The West Bengal Drug Controller approved the licensing of Bengal Chemicals & Pharmaceuticals Ltd. for producing hydroxychloroquine tablets. They have manufactured over 780,000 tablets and they have a demand of over 2 million tablets from over 16 Indian states.
Hydroxychloroquine Market Segmentation:
By Dosage Type
By Application
By Distribution Channel
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Hydroxychloroquine Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Global Hydroxychloroquine Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Hydroxychloroquine Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Hydroxychloroquine Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Hydroxychloroquine Market, By Dosage Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. 100mg 7.2. 200mg 7.3. 300mg 8. Global Hydroxychloroquine Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Malaria 8.2. COVID-19 8.3. Rheumatoid Arthritis 8.4. Q Fever 8.5. PCT 8.6. Others 9. Global Hydroxychloroquine Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 9.4. Speciality Drug Stores 10. North America Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Latin America Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2020-2027 12. Europe Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2020-2027 13. Asia Pacific Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. Novartis International AG 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Sanofi S.A. 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Amneal Pharmaceuticals, Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Laurus Labs Limited 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Prasco Laboratories 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Cardinal Health 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Concordia Pharmaceuticals Inc. 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Intas Pharmaceuticals 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Cipla 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. McW Healthcare of Indore 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. Macleods Pharmaceuticals 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12. Bengal Chemicals & Pharmaceuticals Ltd. 15.12.1. Company Overview 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13. Dr. Reddy's Laboratories 15.13.1. Company Overview 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14. Covis Pharmaceuticals, Inc. 15.14.1. Company Overview 15.14.2. Product Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 15.15. Aphena Pharma Solutions Tennessee, Inc. 15.15.1. Company Overview 15.15.2. Product Portfolio 15.15.3. SWOT Analysis 15.15.4. Financial Overview 15.15.5. Strategic Overview 15.16 Mylan N.V. 15.16.1. Company Overview 15.16.2. Product Portfolio 15.16.3. SWOT Analysis 15.16.4. Financial Overview 15.16.5. Strategic Overview 15.17. McKesson Corporation 15.17.1. Company Overview 15.17.2. Product Portfolio 15.17.3. SWOT Analysis 15.17.4. Financial Overview 15.17.5. Strategic Overview 15.18. Lupin Pharmaceutical 15.18.1. Company Overview 15.18.2. Product Portfolio 15.18.3. SWOT Analysis 15.18.4. Financial Overview 15.18.5. Strategic Overview 15.19. Sun Pharmaceutical Industries Ltd. 15.19.1. Company Overview 15.19.2. Product Portfolio 15.19.3. SWOT Analysis 15.19.4. Financial Overview 15.19.5. Strategic Overview 15.20. Ipca Laboratories 15.20.1. Company Overview 15.20.2. Product Portfolio 15.20.3. SWOT Analysis 15.20.4. Financial Overview 15.20.5. Strategic Overview 15.21. Teva Pharmaceutical Industries Ltd 15.21.1. Company Overview 15.21.2. Product Portfolio 15.21.3. SWOT Analysis 15.21.4. Financial Overview 15.21.5. Strategic Overview 15.22. Zydus Cadila 15.22.1. Company Overview 15.22.2. Product Portfolio 15.22.3. SWOT Analysis 15.22.4. Financial Overview 15.22.5. Strategic Overview 15.23. Wallace Pharmaceuticals 15.23.1. Company Overview 15.23.2. Product Portfolio 15.23.3. SWOT Analysis 15.23.4. Financial Overview 15.23.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
1. Market Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.3.2 Market Covered
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2. Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3. Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.3 Competitive Insights
4. Global Hydroxychloroquine Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework
4.6.1. Reimbursement Framework
4.6.2. Standards And Compliances
5. Global Hydroxychloroquine Market Overview
5.1. Market Dynamics
5.1.1. Market Driver Analysis
5.1.1.1. Increasing focus of Hydroxychloroquine Companies on Brand Protection
5.1.1.2. Untapped Opportunities in Emerging Regions
5.1.2. Market Restraint Analysis
5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
5.1.3. Industry Challenges
5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Hydroxychloroquine Market Analysis Tools
6.1. Industry Analysis - Porter’s
6.1.1. Supplier Power
6.1.2. Buyer Power
6.1.3. Substitution Threat
6.1.4. Threat from New Entrants
6.1.5. Competitive Rivalry
6.2. Pestel Analysis
6.2.1. Political Landscape
6.2.2. Environmental Landscape
6.2.3. Social Landscape
6.2.4. Technology Landscape
6.2.5. Legal Landscape
6.3. Major Deals And Strategic Alliances Analysis
6.3.1. Joint Ventures
6.3.2. Mergers and Acquisitions
6.3.3. Licensing and Partnership
6.3.4. Technology Collaborations
6.3.5. Strategic Divestments
6.4. Market Entry Strategies
6.5. Case Studies
7. Global Hydroxychloroquine Market, By Dosage Type Historical Analysis and Forecast 2020-2027 (USD Million)
7.1. 100mg
7.2. 200mg
7.3. 300mg
8. Global Hydroxychloroquine Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
8.1. Malaria
8.2. COVID-19
8.3. Rheumatoid Arthritis
8.4. Q Fever
8.5. PCT
8.6. Others
9. Global Hydroxychloroquine Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)
9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Online Pharmacy
9.4. Speciality Drug Stores
10. North America Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
10.1. Introduction
10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
10.2.1. U.S.A
10.2.2. Canada
10.2.3. Mexico
10.3. Market Size (USD Million) Forecast for North America 2020-2027
11. Latin America Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
11.1. Introduction
11.2. Regional Market Trends
11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
11.3.1. Brazil
11.3.2. Venezuela
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Market Size (USD Million) Forecast for Latin America 2020-2027
12. Europe Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
12.2.1. Germany
12.2.2. U.K
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Poland
12.2.8. Switzerland
12.2.9. Rest of Western Europe
12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
13.1. Introduction
13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
13.2.1. Japan
13.2.2. China
13.2.3. Singapore
13.2.4. India
13.2.5. Australia and New Zealand
13.2.6. ASEAN
13.2.7. South Korea
13.2.8. Taiwan
13.2.9. Rest of Asia Pacific
13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Hydroxychloroquine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
14.1. Introduction
14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
14.2.1. Saudi Arabia
14.2.2. UAE
14.2.3. South Africa
14.2.4. Egypt
14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
15.1. Novartis International AG
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.3. SWOT Analysis
15.1.4. Financial Overview
15.1.5. Strategic Overview
15.2. Sanofi S.A.
15.2.1. Company Overview
15.2.2. Product Portfolio
15.2.3. SWOT Analysis
15.2.4. Financial Overview
15.2.5. Strategic Overview
15.3. Amneal Pharmaceuticals, Inc.
15.3.1. Company Overview
15.3.2. Product Portfolio
15.3.3. SWOT Analysis
15.3.4. Financial Overview
15.3.5. Strategic Overview
15.4. Laurus Labs Limited
15.4.1. Company Overview
15.4.2. Product Portfolio
15.4.3. SWOT Analysis
15.4.4. Financial Overview
15.4.5. Strategic Overview
15.5 Prasco Laboratories
15.5.1. Company Overview
15.5.2. Product Portfolio
15.5.3. SWOT Analysis
15.5.4. Financial Overview
15.5.5. Strategic Overview
15.6 Cardinal Health
15.6.1. Company Overview
15.6.2. Product Portfolio
15.6.3. SWOT Analysis
15.6.4. Financial Overview
15.6.5. Strategic Overview
15.7. Concordia Pharmaceuticals Inc.
15.7.1. Company Overview
15.7.2. Product Portfolio
15.7.3. SWOT Analysis
15.7.4. Financial Overview
15.7.5. Strategic Overview
15.8. Intas Pharmaceuticals
15.8.1. Company Overview
15.8.2. Product Portfolio
15.8.3. SWOT Analysis
15.8.4. Financial Overview
15.8.5. Strategic Overview
15.9. Cipla
15.9.1. Company Overview
15.9.2. Product Portfolio
15.9.3. SWOT Analysis
15.9.4. Financial Overview
15.9.5. Strategic Overview
15.10. McW Healthcare of Indore
15.10.1. Company Overview
15.10.2. Product Portfolio
15.10.3. SWOT Analysis
15.10.4. Financial Overview
15.10.5. Strategic Overview
15.11. Macleods Pharmaceuticals
15.11.1. Company Overview
15.11.2. Product Portfolio
15.11.3. SWOT Analysis
15.11.4. Financial Overview
15.11.5. Strategic Overview
15.12. Bengal Chemicals & Pharmaceuticals Ltd.
15.12.1. Company Overview
15.12.2. Product Portfolio
15.12.3. SWOT Analysis
15.12.4. Financial Overview
15.12.5. Strategic Overview
15.13. Dr. Reddy's Laboratories
15.13.1. Company Overview
15.13.2. Product Portfolio
15.13.3. SWOT Analysis
15.13.4. Financial Overview
15.13.5. Strategic Overview
15.14. Covis Pharmaceuticals, Inc.
15.14.1. Company Overview
15.14.2. Product Portfolio
15.14.3. SWOT Analysis
15.14.4. Financial Overview
15.14.5. Strategic Overview
15.15. Aphena Pharma Solutions Tennessee, Inc.
15.15.1. Company Overview
15.15.2. Product Portfolio
15.15.3. SWOT Analysis
15.15.4. Financial Overview
15.15.5. Strategic Overview
15.16 Mylan N.V.
15.16.1. Company Overview
15.16.2. Product Portfolio
15.16.3. SWOT Analysis
15.16.4. Financial Overview
15.16.5. Strategic Overview
15.17. McKesson Corporation
15.17.1. Company Overview
15.17.2. Product Portfolio
15.17.3. SWOT Analysis
15.17.4. Financial Overview
15.17.5. Strategic Overview
15.18. Lupin Pharmaceutical
15.18.1. Company Overview
15.18.2. Product Portfolio
15.18.3. SWOT Analysis
15.18.4. Financial Overview
15.18.5. Strategic Overview
15.19. Sun Pharmaceutical Industries Ltd.
15.19.1. Company Overview
15.19.2. Product Portfolio
15.19.3. SWOT Analysis
15.19.4. Financial Overview
15.19.5. Strategic Overview
15.20. Ipca Laboratories
15.20.1. Company Overview
15.20.2. Product Portfolio
15.20.3. SWOT Analysis
15.20.4. Financial Overview
15.20.5. Strategic Overview
15.21. Teva Pharmaceutical Industries Ltd
15.21.1. Company Overview
15.21.2. Product Portfolio
15.21.3. SWOT Analysis
15.21.4. Financial Overview
15.21.5. Strategic Overview
15.22. Zydus Cadila
15.22.1. Company Overview
15.22.2. Product Portfolio
15.22.3. SWOT Analysis
15.22.4. Financial Overview
15.22.5. Strategic Overview
15.23. Wallace Pharmaceuticals
15.23.1. Company Overview
15.23.2. Product Portfolio
15.23.3. SWOT Analysis
15.23.4. Financial Overview
15.23.5. Strategic Overview
16. Impact of COVID-19
16.1. Positive influence on the healthcare industry
16.2. The financial disruption of the manufacturing sector
16.3. Impact of COVID-19 on emerging companies
16.4. Significant mandates in the healthcare regulations initiated by administrations
16.5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics